GLP1R and type 2 diabetes mellitus: Finally, results from large scale CVOTs have now revealed that many but not all GLP-1R agonists yield significant improvements in cardiovascular health in people with T2DM, suggesting that use of these agents is likely to increase due to the importance of managing cardiovascular risk in these individuals.